Advanced search
Publication Cover
Postgraduate Medicine Volume 101, 1997 - Issue 6
Submit an article Journal homepage
15
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Treating Alzheimer's disease

Pharmacologic options now and in the near future

Pierre N. Tariot Dr Tariot is associate professor, departments of psychiatry, medicine, and neurology, and Dr Porsteinsson is assistant professor, department of psychiatry, University of Rochester School of Medicine, Rochester, New York.
, MD,
Lon Schneider Dr Schneider is professor, departments of psychiatry and neurology, University of Southern California School of Medicine, Los Angeles.
, MD &
Anton P. Porsteinsson Dr Tariot is associate professor, departments of psychiatry, medicine, and neurology, and Dr Porsteinsson is assistant professor, department of psychiatry, University of Rochester School of Medicine, Rochester, New York.
, MD
Pages 73-90 | Published online: 30 Jun 2015

References

  • Tariot PN. Neurobiology and treatment of dementia. In: Salzman C, ed. Clinical geriatric psychopharmacology. 2d ed. Baltimore: Williams & Wilkins, 1992: 277–99
  • Tariot PN, Schneider LS, Coleman PD. Treatment of Alzheimer's disease: glimmers of hope? Chem Indus 1993; 20:801–7
  • Schneider LS, Tariot PN. Emerging drugs for Alzheimer's disease: mechanisms of action and prospects for cognitive enhancing medications. Med Clin North Am 1994; 78(4):911–34
  • Schneider LS, Tariot PN. Cognitive enhancers for Alzheimer's disease. In: Tasman A, Kay J, Lieberman J, eds. Psychiatry. Philadelphia: Saunders, 1997: 1685–1702
  • Tariot PN, Schneider LS. Contemporary treatment approaches to Alzheimer's disease. Consult Pharm 1996; 11(Suppl E):16–24
  • Schneider LS, Tariot PN, Small GW. Update on treatment for Alzheimer's disease and other dementias. In: Rosenbaum J, Dunner D, eds. Psychiatr Clin North Am: Annual of Drug Therapy. Philadelphia: Saunders, 1997: 135–66
  • Tariot PN, Schneider LS, Katz IR. Anticonvulsant and other non-neuroleptic treatment of agitation in dementia. J Geriatr Psychiatry Neurol 1995; 8(Suppl 1): S28–39
  • Tariot PN. Treatment strategies for agitation and psychosis in dementia. J Clin Psychiatry 1996; 57(Suppl 14):21–9
  • Harrell LE, Callaway R, Morere D, et al. The effect of long-term physostigmine administration in Alzheimer's disease. Neurology 1990; 40(9):1350–4
  • Summers WK, Majovski LV, Marsh GM, et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315(20):1241–5
  • Tacrine Study Group. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268(18):2523–9
  • Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271(13):985–91
  • Tacrine Study Group. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996; 47(1):166–77
  • Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol 1996; 9(1):1–6
  • Rogers SL, Friedhoff LT. E2020 improves cognition and quality of life in patients with mild-to-moderate Alzheimer's disease: results of a phase-II trial. Neurology 1994; 44(Suppl 2):A165
  • Rogers SL, Doody R, Mohs R, et al. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30-week phase III trial. Neurology 1996; 46:A217
  • Rogers SL, Friedhoff LT. Donepezil (E2020) produces long-term clinical improvement in Alzheimer's disease. Presented at the 4th International Nice/Springfield Symposium on Advances in Alzheimer Therapy. Nice, France: 1996 Apr
  • Anand R, Gharabawi G. Efficacy and safety results of the early phase studies with Exelon (ENA 713) in Alzheimer's disease: an overview. J Drug Dev Clin Practice 1996; 8:1–14
  • Tariot PN, Schneider LS, Patel SV, et al. Alzheimer's disease and (-)deprenyl: rationales and findings. In: Szelenyi I, ed. Inhibitors of monoamine oxidase B: pharmacology and clinical use in neurodegenerative disorders. Basel, Switzerland: Birkhauser 1993: 301–17
  • Olsson L, Nordberg A, Von Holst H, et al. Nerve growth factor affects “C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). Neurobiol Aging 1989; 10:205–7
  • Ohkura T, Isse K, Akazawa K, et al. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. EndocrJ 1994;41(4):361–71
  • Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 1994; 151(8): 1105–13

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.